Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety ...
PharmiWeb

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pillApproval supported by four phase 3 studies that met ...
Pharmabiz

Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints

Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...

Fire weather watch issued in Oklahoma after wildfire evacuations, power outages

Thousands of Oklahomans evacuated Sunday as wildfires spread across the state, fueled by strong winds and high temps. Here's what to expect Monday.